Search clinical trials for: B12019 and Neulasta

Total 271454 results

Cinfa Biotech

Completed

Immunogenicity and Pharmacodynamic of B12019 and Neulasta® in Healthy Subjects

Healthy Volunteers

Germany
Cinfa Biotech

Completed

Pharmacokinetic and Pharmacodynamics of B12019 and Neulasta® in Healthy Subjects

Clinical Pharmacology

Germany
Coherus Biosciences, Inc.

Completed

Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®

Immunity, Humoral

United States
Sandoz
Sandoz GmbH

Completed

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim (PROTECT2)

Breast Cancer | Chemotherapy-induced Neutropenia

Spain, United States, Argentina, Chile, India, Malaysia, Puerto Rico, Russian Federation
Dartmouth-Hitchcock Medical Center

Terminated

Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies

Hematologic Malignancies

United States
Seoul National University Hospital
Green Cross Corporation

Completed

Pharmacokinetics and Pharmacodynamics of a Novel Pegylated Recombinant Human Granulocyte-Colony Stimulating Factor (GCPGC)

Healthy

Korea, Republic of
Amgen

Completed

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

Breast Cancer | Non-Hodgkin's Lymphoma | Ovarian Cancer | Lung Cancer | Neutropenia
Intas Pharmaceuticals, Ltd.
Lambda Therapeutic Research Ltd.

Completed

Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.

Pharmacokinetic Bioequivalence Study in Human Healthy Volunteers

India
Intas Pharmaceuticals, Ltd.
Lambda Therapeutic Research Ltd.

Completed

Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.

Healthy Volunteers | Immunogenicity

India
University Hospital, Clermont-Ferrand
Amgen

Unknown

Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5) (MEG-5)

Solid Malignancies

France
Amgen

Completed

Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy

Non-Small Cell Lung Cancer
Pfizer
Hospira, now a wholly owned subsidiary of Pfizer

Completed

A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants

Neutropenia

Australia
EVIVE Biotechnology

Completed

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia

United States
Qilu Pharmaceutical Co., Ltd.

Unknown

A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects

Healthy

Germany, United Kingdom
Hospital Universitario Dr. Jose E. Gonzalez

Completed

Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant

Lymphoma | Myeloma Multiple

Mexico
Fresenius Kabi SwissBioSim GmbH

Completed

Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects

Healthy

Australia
Coherus Biosciences, Inc.

Completed

Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta

Healthy

United States
Coherus Biosciences, Inc.

Completed

Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)

Bioequivalence

United States
Pfizer

Completed

A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers

Healthy Volunteers

United States
Fresenius Kabi SwissBioSim GmbH

Completed

Safety and Immunogenicity of MSB11455 in Healthy Participants

Healthy

New Zealand
Hospira, now a wholly owned subsidiary of Pfizer

Completed

Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating Pegfilgrastim Hospira Compared to Neulasta (Amgen) in Healthy Volunteers

Healthy

United Kingdom
Boryung Pharmaceutical Co., Ltd

Completed

A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects

Hypertension | Diabetes Mellitus, Type 2

Korea, Republic of
University Hospital Tuebingen

Completed

Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma

Non-Hodgkin Lymphoma

Germany
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"

Type 2 Diabetes Mellitus | Essential Hypertension

Korea, Republic of
Buddhist Tzu Chi General Hospital

Recruiting

The Neuroprotective Effect of PEG-GCSF in the Traumatic Optic Neuropathy

Traumatic Optic Neuropathy

Taiwan
Gedeon Richter Plc.

Completed

Study to Compare the Pharmacokinetics and Pharmacodynamics of 6 mg RGB-02 to 6 mg Neulasta

Bioequivalence

United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia (AVOID)

Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia

Germany, Italy, Spain
Coherus Biosciences, Inc.
Community Clinical Oncology Research Network, LLC

Unknown

An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca (POEM)

Febrile Neutropenia | Non-myeloid Malignancy

United States
Sandoz
Sandoz GmbH

Completed

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta® (PROTECT-1)

Breast Neoplasms | Chemotherapeutic Toxicity | Chemotherapy-induced Neutropenia | Neutropenic Complications

Russian Federation, Brazil, India, Mexico, Romania, Ukraine
Adello Biologics, LLC
Celerion

Completed

Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects (TPI-120)

Healthy Volunteers

United States
M.D. Anderson Cancer Center
Amgen

Completed

Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma

Multiple Myeloma

United States
Lupin Ltd.

Completed

Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer

Breast Cancer

India
Hanmi Pharmaceutical Company Limited

Completed

Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects

Healthy

United States
Green Cross Corporation
Symyoo

Completed

GCPGC in Chemotherapy-induced Neutropenia

Chemotherapy Induced Neutropenia

Korea, Republic of
Adello Biologics, LLC
inVentiv Health Clinical

Completed

Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects (TPI-120)

Healthy Volunteers

United States
Universitaire Ziekenhuizen KU Leuven
St-Augustinus Wilrijk

Completed

Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer

Breast Cancer

Belgium
Bio Genuine (Shanghai) Biotech Co., Ltd.

Recruiting

Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis

Endometriosis | Moderate to Severe Endometriosis-associated Pain

China
Mylan Inc.
Mylan GmbH

Completed

Pharmacokinetic / Pharmacodynamic Study Comparing MYL-1401H, EU-sourced Neulasta and US-licensed Neulasta

Healthy Volunteers

Netherlands
Amgen

Completed

ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer

Breast Cancer
AstraZeneca

Terminated

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Previously Treated Non Small Cell Lung Cancer

United States
EVIVE Biotechnology

Completed

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia

United States
Iterion Therapeutics

Completed

Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059

Desmoid Tumor

United States, Canada
Bio Genuine (Shanghai) Biotech Co., Ltd.

Recruiting

Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids.

Uterine Fibroids | Heavy Menstrual Bleeding

China
InnoBM Pharmaceuticals Co., Ltd.

Recruiting

BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors (BM201-1001)

Advanced Solid Tumors

China
Rabin Medical Center
Tel-Aviv Sourasky Medical Center; Soroka University Medical Center

Unknown

Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma

Lymphoma | Neutropenia

Israel
Nanogen Pharmaceutical Biotechnology Joint Stock...

Completed

Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.

Breast Cancer Female

Vietnam
Ottawa Hospital Research Institute

Active, not recruiting

A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy

Early-stage Breast Cancer

Canada
Accure Therapeutics
Simbec Research

Completed

BN201 SAD MAD Study in Healthy Subjects

Optic Neuritis | Optic; Neuritis, With Demyelination

United Kingdom
Armando Santoro, MD

Completed

Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy

Tumors | Hematological Neoplasms

Italy
Hoffmann-La Roche

Completed

An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma

Colombia, Mexico

3

Subscribe